NeOnc Will Meet With FDA on November 17, 2026
The company scheduled a Type B meeting to discuss the future registrational development of its drug candidate, NEO212.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should the FDA use accelerated approval pathways more frequently for new, unproven brain cancer treatments?
NeOnc Technologies will hold an End-of-Phase 1 meeting with the FDA on November 17, 2026, at the White Oak campus in Silver Spring, Maryland. The discussion will focus on trial design and potential accelerated approval pathways for NEO212.
Why it matters
The meeting serves as a crucial regulatory step to align on the evidence required for a future marketing application. NeOnc plans to seek FDA feedback on patient population and endpoints to advance its clinical development strategy.
NeOnc completed the Phase 1 dose-escalation of NEO212, which showed a 60% tumor reduction in one glioblastoma patient. One lung cancer patient also experienced 16 months of stable disease during the study.
The players
NeOnc Technologies
This is a Calabasas-based biotechnology company focused on developing therapies for cancer patients.
FDA
The Food and Drug Administration is the federal agency responsible for overseeing the safety and efficacy of medical products in the United States.
The details
The FDA authorized NeOnc to initiate Phase 2a and 2b testing in September 2025. During the upcoming meeting, the company will review data from its dose-escalation trials, which used a once-daily administration schedule for five days of every 28-day cycle.
Timeline
September 2025: The FDA authorized NeOnc to move forward with Phase 2a and 2b clinical trials.
September 28, 2026: NeOnc announced its upcoming End-of-Phase 1 meeting with federal regulators.
November 17, 2026: The company will meet with the FDA at the White Oak campus in Silver Spring, Maryland.
Health Landscape
This meeting marks a strategic step toward aligning clinical trial endpoints with the FDA's accelerated approval pathway. It follows a shift in oncology research, where companies increasingly prioritize data from specific dose-escalation trials to secure expedited regulatory paths.
This regulatory update provides insight into the potential timeline for bringing new glioblastoma and lung cancer treatments to market. Patients and providers should monitor the meeting outcomes as they will dictate the next stages of clinical access to NEO212.
The takeaway
The upcoming meeting represents a pivotal check-in for the drug developer as it navigates the path from successful Phase 1 results to larger trials. Future trial design and drug availability will depend heavily on the regulatory guidance provided during this session.
What happens next
NeOnc Technologies is scheduled to hold its End-of-Phase 1 meeting with the FDA at the White Oak campus in Silver Spring, Maryland, on November 17, 2026.
Further reading
Learn more about the latest developments in oncological research on our Cancer page.
More information
For more information on the development program, visit the NeOnc official company information.
Live Poll
Should the FDA use accelerated approval pathways more frequently for new, unproven brain cancer treatments?
